Results 1 to 10 of about 46,971 (258)
The universal administration of pneumococcal conjugate vaccines (PCVs) had been demonstrated as an effective way to prevent Streptococcus pneumoniae infection.
Qian-qian Du+3 more
doaj +2 more sources
Introduction: Pneumococcal diseases (including septicemia, meningitis, pneumonia, and upper respiratory infections) constitute a major public health problem.
Tomas Mrkvan+4 more
doaj +2 more sources
Strengths and weaknesses of pneumococcal conjugate vaccines
Multivalent vaccines addressing an increasing number of Streptococcus pneumoniae types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years.
F. Micoli+4 more
semanticscholar +3 more sources
Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia [PDF]
Limited data from Asia are available on long-term effects of pneumococcal conjugate vaccine introduction on pneumococcal carriage. Here we assess the impact of 13-valent pneumococcal conjugate vaccine (PCV13) introduction on nasopharyngeal pneumococcal ...
Claire von Mollendorf+19 more
doaj +2 more sources
Development of a pneumococcal conjugate vaccine [PDF]
George R. Siber
openalex +3 more sources
In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years ...
Miwako Kobayashi+11 more
semanticscholar +1 more source
The 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Merck Sharp & Dohme LLC]) have been recommended for U.S.
Miwako Kobayashi+50 more
semanticscholar +1 more source
This cohort study estimates the association between vaccination with 13-valent pneumococcal conjugate vaccine and hospitalizations for all-cause pneumonia and lower respiratory tract infection among older adults in a large health care system in ...
Amber Hsiao+8 more
semanticscholar +1 more source
Background Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease, but disease from non-PCV serotypes remains. The safety, tolerability, and immunogenicity of a 20-valent PCV (PCV20) were evaluated.
B. Essink+14 more
semanticscholar +1 more source
Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes.
Sweta M Patel+15 more
doaj +3 more sources